Tofacitinib controlled release - Triastek
Alternative Names: T-21 - TriastekLatest Information Update: 28 Aug 2023
At a glance
- Originator Triastek
- Class 2 ring heterocyclic compounds; Amides; Anti-inflammatories; Antiasthmatics; Antineoplastics; Antipsoriatics; Antirheumatics; Eye disorder therapies; Irritable bowel syndrome therapies; Nitriles; Piperidines; Pyrimidines; Pyrroles; Skin disorder therapies; Small molecules
- Mechanism of Action Janus kinase 1 inhibitors; Janus kinase 2 inhibitors; Janus kinase 3 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Clinical Phase Unknown Ulcerative colitis